Technologies

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.

The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.

Nowadays, to properly design and develop advanced materials capable to preserve for long times their performance under aggressive environments such as power generation plants, renewables, nuclear reactors and electronics of new generation, transport on ground and on space, aeronautics, catalysis, biomedical implants, the optimization of metallurgical processes involved is crucial.

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.

This technology is an e-health application. The DragONE application is inspired by the global guidelines for the management of asthma, which promote the opportunity to implement a multidimensional assessment of pediatric asthma using innovative systems. DragONE allows to record data on the subjective control of asthma, by using easy-to-understand colors and icons for children (red, yellow or green dragon), to keep track to the patient’s of perceived state.

INCIPIT technology allowed the implementation of a multifunctional, micro-structured and electroconductive therapeutic product to treat patients with myocardial infarction, the leading cause of death for cardiovascular disease.  Current therapies (drugs, bypass, angioplasty) do not restore the functionality of damaged myocardial tissue.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

The systems simulate, with high reproducibility, the conditions that occur in the different compartments of the gastrointestinal tracts and are promising to accurately mimic the digestive process, with the possibility to evaluate bioaccessibility and bioavailability. Moreover, the systems permit to study the synergic and reciprocal effects between the bioactive compounds characteristic of food and intestinal microbiota.

Plants can compete favorably with traditional expression systems (mammalian cells, yeasts or bacteria) to produce recombinant proteins/peptides of pharmaceutical/industrial/agrifood interest. This technology names “Plant Molecular Farming”. The CNR-IBBA research team offers the study of new strategies for the expression and optimization of recombinant proteins/peptides in plant-based systems (plant tissues, transgenic plants, plant cell culture). Our pipeline is based on the following modules:

The development of an innovative screening platform of natural marine extracts guided by biological assays represents one of the main products developed within the Antitumor Drugs and Vaccines from the SEA (ADViSE) project which aims to provide a new vision in Drug Discovery processes.

The proposed system is based on a high-resolution electrocardiograph in which the electrodes are positioned on maternal abdomen. The acquired signals are processed using a completely unsupervised software for fetal ECG extraction based on independent component analysis, maternal ECG canceling and a quality index optimization. The electrocardiograph is constituted by a light-weight and light-dimension portable unit, which acquires the signals and transmit them to a computer where the analysis software runs.

SITODIET is an innovative software that supports a translational approach to health’s state. It integrates various sources of physiological, behavioral, and psychological data to reduce the risks associated with the onset of lifestyle-related diseases (primary prevention), to support health professionals in early diagnosis (secondary prevention) or to manage the personalized therapy’s patient (tertiary prevention). SITODIETcollects data automatically, through actigraphy tools, as wristband or smartwatch, or manually

This technology is based on an algorithm able to provide the probability of being asthmatic with high accuracy. This probability is based on the evaluation of respiratory function and, specifically, of forced expiratory vital capacity in the first second (FEV₁), in resting conditions, and 20 minutes after administration of a bronchodilator drug.

IMM has developed tactile sensors for the detection of objects and surface and for the handling of objects with humanoid robots (e-skin). These devices can be integrated on ultra-flexible and high conformable substrates and they can be used for multiple applications: 1) for a correct interaction with objects distributed in complex environment; 2) for a safe short-range interaction between humanoid robot and humans; 3) for fabricating smart wearables for the detection of biometric parameters (e.g. heartbeat); 4) for remotely control rovers with wearable gadgets.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.